### Thursday, 30th January 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs/Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:15</td>
<td>Opening Ceremony</td>
<td>C. Chabannon &amp; H. Einsele</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>(Chairs of the Scientific Programme Committee)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. Kröger &amp; J. Gribben <em>(President EBMT &amp; President EHA)</em></td>
</tr>
<tr>
<td>12:15 - 12:45</td>
<td>Session I: Keynote Lecture</td>
<td>Chairs: C. Chabannon &amp; H. Einsele</td>
</tr>
<tr>
<td></td>
<td>Informed design of engineered T cell therapies for cancer</td>
<td>S. Riddell <em>(United States)</em></td>
</tr>
<tr>
<td>12:45 - 13:15</td>
<td>Session II: Indications for CAR T Cell therapy</td>
<td>Chairs: N. Kröger &amp; J. Gribben</td>
</tr>
<tr>
<td></td>
<td>Acute leukemia</td>
<td>A. Nagler <em>(Israel)</em></td>
</tr>
<tr>
<td>13:15 - 13:45</td>
<td>Lymphoma</td>
<td>H. Einsele <em>(Germany)</em></td>
</tr>
<tr>
<td>13:45 - 14:15</td>
<td>Lymphoma</td>
<td>C. Thieblemont <em>(France)</em></td>
</tr>
<tr>
<td></td>
<td>Session III: Improving the efficacy and safety profile</td>
<td>Chairs: M. Hudecek &amp; C. MacKall</td>
</tr>
<tr>
<td>14:15 - 14:35</td>
<td>Targeted genomic insertion</td>
<td>D. Büsch <em>(Germany)</em></td>
</tr>
<tr>
<td>14:35 - 14:55</td>
<td>Virus-free gene transfer &amp; genome editing</td>
<td>Z. Ivics <em>(Germany)</em></td>
</tr>
<tr>
<td>15:15 - 15:45</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Session IV: Keynote lecture</td>
<td>Chairs: A. Baruchel &amp; M. Heemskerk</td>
</tr>
<tr>
<td></td>
<td>Engineering Next Generation CAR T cells to Overcome Resistance</td>
<td>C. MacKall <em>(United States)</em></td>
</tr>
<tr>
<td>16:15 - 16:35</td>
<td>Session V: CAR T in pediatrics</td>
<td>Chairs: A. Baruchel &amp; M. Heemskerk</td>
</tr>
<tr>
<td></td>
<td>Post transplant relapse-Second SCT or CAR T-cells</td>
<td>P. Bader <em>(Germany)</em></td>
</tr>
<tr>
<td>16:35 - 16:55</td>
<td>Neuroblastoma</td>
<td>F. Locatelli <em>(Italy)</em></td>
</tr>
<tr>
<td>16:55 - 17:15</td>
<td>Bispecific CAR T Cells</td>
<td>P. Amrolia <em>(United Kingdom)</em></td>
</tr>
<tr>
<td>17:15 - 17:45</td>
<td>Session VI: Keynote Lecture</td>
<td>Chairs: C. Chabannon &amp; H. Einsele</td>
</tr>
<tr>
<td></td>
<td>Improved CAR T cell approaches for lymphoid malignancies</td>
<td>M. Pule <em>(United Kingdom)</em></td>
</tr>
<tr>
<td></td>
<td>Oral presentations:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Madduri <em>(US)</em></td>
<td>M. Keränen <em>(Finland)</em></td>
</tr>
<tr>
<td></td>
<td>RM. Monjezi <em>(Germany)</em></td>
<td>B. de Angelis <em>(Italy)</em></td>
</tr>
<tr>
<td></td>
<td>E. Donnadieu <em>(France)</em></td>
<td>S. Tettamanti <em>(Italy)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Greco <em>(Italy)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CF. Magnani <em>(Italy)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MJ. Kersten <em>(Netherlands)</em></td>
</tr>
<tr>
<td>18:45 - 19:30</td>
<td>Satellite Symposium sponsored by Celgene</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recent Advances in CAR T cell therapy for haematological malignancies</td>
<td>J. Abramson <em>(United States)</em> &amp; MV. Mateos <em>(Spain)</em></td>
</tr>
<tr>
<td></td>
<td>Chair: J. Abramson</td>
<td></td>
</tr>
<tr>
<td>19:30 - 20:30</td>
<td>Welcome reception &amp; poster session</td>
<td></td>
</tr>
</tbody>
</table>
# Friday, 31st January 2020

<table>
<thead>
<tr>
<th>Session VII: Latest clinical &amp; pre-clinical data, Part 1</th>
<th>Chairs: J. Kuball &amp; B. Levine</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 - 8:50 ROR1 CAR T cell therapy in CLL and solid tumors</td>
<td>J. Specht (United States)</td>
</tr>
<tr>
<td>8:50 - 9:10 Novel CAR targets for multiple myeloma</td>
<td>N. Hosen (Japan)</td>
</tr>
<tr>
<td>9:10 - 9:30 Liso-cel pivotal TRANSCEND data</td>
<td>J. Abramson (United States)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session IX: Keynote Lecture</th>
<th>Chairs: J. Kuball &amp; B. Levine</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 - 10:00 Updates in CAR T cell therapy</td>
<td>C. June (United States)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session X: Latest clinical &amp; pre-clinical data, Part 2</th>
<th>Chairs: J. Kuball &amp; B. Levine</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:20 CD30 memory T cells for Hodgkin and T cell lymphoma</td>
<td>J. Briones (Spain)</td>
</tr>
<tr>
<td>10:20 - 10:40 L1CAM-specific CAR T cell therapy for childhood neuroblastoma</td>
<td>A. Künkele (Germany)</td>
</tr>
<tr>
<td>10:40 - 11:00 iP5 CARs</td>
<td>M. Themeli (Netherlands)</td>
</tr>
</tbody>
</table>

### Coffee break

<table>
<thead>
<tr>
<th>Session XI: Best Abstracts &amp; Flash Talks - Part 2</th>
<th>Chairs: M. Hudecek &amp; A. Urbano-Ispizu</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 12:30 Oral Presentations:</td>
<td>Flash talks:</td>
</tr>
<tr>
<td>M. Seif (Germany)</td>
<td>A. Alonso-Saldivides (Spain)</td>
</tr>
<tr>
<td>M. Doglio (Italy)</td>
<td>A. Fernandez (Spain)</td>
</tr>
<tr>
<td>S. Lykopoulous (United Kingdom)</td>
<td>W. Hazelton (UK)</td>
</tr>
<tr>
<td>12:30 - 13:00 Current CAR T Trial activities in China</td>
<td>JX. Wang (China)</td>
</tr>
</tbody>
</table>

### Lunch break

### Satellite Symposium sponsored by Kite (a Gilead Company)

**Redefining survival in DLBCL: The role of CAR T**

**Chair:** A. Sureda

A. Sureda, R. Sanderson & N. Bolaños

<table>
<thead>
<tr>
<th>Session XII: Keynote Lecture</th>
<th>Chairs: M. Hudecek &amp; A. Urbano-Ispizu</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 15:00 The emergence of synthetic immunity</td>
<td>M. Sadelain (United States)</td>
</tr>
</tbody>
</table>

### Session XIV: CAR Effector Cells | Chairs: I. Yakoub-Agha & D. Büsch |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:20 CAR expressing NK cells for cancer retargeting</td>
<td>K. Rezvani (United States)</td>
</tr>
<tr>
<td>15:20 - 15:40 Allogeneic CAR T cells</td>
<td>W. Qasim (United Kingdom)</td>
</tr>
<tr>
<td>15:40 - 16:00 CAR-NK cells as off-the-shelf therapeutics bridging innate and adaptive immunity</td>
<td>W. Wels (Germany)</td>
</tr>
</tbody>
</table>

### Session XV: Optimizing CAR T treatment | Chairs: M. Mohty & P. Pedrazzoli |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:20 Microbiome</td>
<td>M. van den Brink (United States)</td>
</tr>
<tr>
<td>16:20 - 16:40 Visualizing CAR T-cells at work</td>
<td>J. Huppa (Austria)</td>
</tr>
<tr>
<td>16:40 - 17:00 Improving CART-cells in solid tumors</td>
<td>S. Guedan (Spain)</td>
</tr>
</tbody>
</table>

### Coffee break & Industry theater session by BD Biosciences

<table>
<thead>
<tr>
<th>Session XVI: CAR T regulatory session</th>
<th>Chairs: N. Bolaños &amp; W. Herr</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30 - 17:52 Marketing authorization of CAR T cells - the EMA perspective</td>
<td>M. Schüssler-Lenz (Germany)</td>
</tr>
<tr>
<td>17:52 - 18:14 Creating a country-wide selection algorithm (The Austrian experience)</td>
<td>U. Jäger (Austria)</td>
</tr>
<tr>
<td>18:14 - 18:38 PASS and PAES: The need for registration, short- and long-term follow-up of patients treated with gene therapy medicinal products</td>
<td>C. Chabannon (France)</td>
</tr>
<tr>
<td>18:38 - 19:00 Patients’ perspective</td>
<td>B. Verhoeven (Netherlands)</td>
</tr>
</tbody>
</table>

### Satellite Symposium sponsored by Novartis

**CART from the trial design to RWE in DLBCL**

**Chair:** C. Solano

F. Ciceri (Italy) & I. Avivi (Israel)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Introduction and Welcome - C. Chomienne (France)</td>
<td>J. Murray (UK) &amp; E. Aerts (Belgium)</td>
<td>Content of the Advanced Cellular Therapies form</td>
</tr>
<tr>
<td>8:35</td>
<td>The science of IEC and what is new - E. Vickers (UK)</td>
<td>E. Vickers (United Kingdom)</td>
<td>C. Chabannon (France)</td>
</tr>
</tbody>
</table>

**Coffee break & Industry theater session sponsored by Kite (a Gilead Company)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XIX: D M Session 1 Chair: M. Pasquini</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20</td>
<td>CAR T data collection</td>
</tr>
<tr>
<td>9:45</td>
<td>Follow-up of CAR T Cell treatments - The EMA Registry Initiative</td>
</tr>
<tr>
<td>10:15</td>
<td>PASS studies</td>
</tr>
<tr>
<td>10:45</td>
<td>Toxicities in CAR T therapy</td>
</tr>
</tbody>
</table>

**Lunch Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXI: Patient care 2 Chairs: J. Murray &amp; E. Aerts</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Guidelines &amp; Network for IEC - M. Pasquini (United States)</td>
</tr>
<tr>
<td>13:25</td>
<td>Nurse training program - M. Evers (United States)</td>
</tr>
<tr>
<td>13:50</td>
<td>The patient's journey for CAR T cells eligibility/ Relapse post CAR T options - M. Berquier (United States)</td>
</tr>
</tbody>
</table>

**Coffee break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXII: Management of side effects (Round table discussion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>A. Baruchel (France)</td>
</tr>
<tr>
<td>10:30</td>
<td>M. Subklewe (Germany)</td>
</tr>
<tr>
<td>10:45</td>
<td>M. J. Christen (Netherlands)</td>
</tr>
<tr>
<td>11:00</td>
<td>I. Yakoub-Agha (France)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXIII: Implementation of CAR-T Cells in the real world</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Round table discussion - S. Miekle (Sweden)</td>
</tr>
<tr>
<td>13:25</td>
<td>Nursing guidelines and Network for IEC - R. Eissel (United Kingdom)</td>
</tr>
<tr>
<td>13:50</td>
<td>Nurse training program - R. Clout (United Kingdom)</td>
</tr>
</tbody>
</table>

**Coffee break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXIV: Manufacturing of CAR T Cell in an Academic setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Peer-to-peer learning session (P2P) in partnership with industry</td>
</tr>
<tr>
<td>15:22</td>
<td>Reimbursement in Germany, DRG and CAR T - C. Hagg (Germany)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXV: Patient care 3 Chairs: J. Murray &amp; E. Aerts</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Apheresis in Adults and Paediatrics - D. Hutt (Israel)</td>
</tr>
<tr>
<td>13:15</td>
<td>Managing expectations - M. Evers (United States)</td>
</tr>
<tr>
<td>13:30</td>
<td>Psychology and CAR-T - S. Chatzunnerti (United Kingdom)</td>
</tr>
<tr>
<td>13:45</td>
<td>CAR-T ineligible what now? - M. Pasquini (United States)</td>
</tr>
</tbody>
</table>

**Coffee break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXVI: Manufacturing of CAR T cell in an industrial setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Academic - industry partnering to develop innovative CAR-T Cells</td>
</tr>
<tr>
<td>15:22</td>
<td>Industry perspective: price and value of CAR-T products, reimbursement models and overall socioeconomic impact</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXVII: Patient care IV Chair: J. Murray</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Panel Discussion &amp; Meet the experts:</td>
</tr>
<tr>
<td>15:22</td>
<td>M. N. Chonghai (Ireland) &amp; E. Aerts (Switzerland)</td>
</tr>
<tr>
<td>15:44</td>
<td>M. Eissel (Switzerland)</td>
</tr>
<tr>
<td>16:04</td>
<td>R. Clout (United Kingdom)</td>
</tr>
</tbody>
</table>

**Coffee break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXVIII: CAR-T Health Technology Assessment: What is the value of CAR-T? Assessment: What is the value of CAR-T?</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Reimbursement and premium CAR T - C. Uyl-de Groot (Netherlands)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXIX: Physicists Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>A. van Baezen (Belgium)</td>
</tr>
<tr>
<td>15:22</td>
<td>J. Sindermann (Belgium)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXX: Nursing guidelines and Network for IEC - M. Pasquini (United States)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Peer-to-peer learning session (P2P) in partnership with industry</td>
</tr>
<tr>
<td>15:22</td>
<td>Reimbursement in Germany, DRG and CAR T - C. Hagg (Germany)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXXI: Case discussions: Part II</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>C. Bonini (Belgium) &amp; C. Chomienne (France)</td>
</tr>
<tr>
<td>15:22</td>
<td>C. Rössig (Belgium) &amp; M. Mohty (Belgium)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXXII: Industry perspective: price and value of CAR-T products, reimbursement models and overall socioeconomic impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>CAR-T Health Technology Assessment: What is the value of CAR-T? Assessment: What is the value of CAR-T?</td>
</tr>
<tr>
<td>16:26</td>
<td>E. Otsuki (Switzerland)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXXIII: Panel Discussion &amp; Meet the experts:</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>M. N. Chonghai (Ireland) &amp; E. Aerts (Switzerland)</td>
</tr>
<tr>
<td>16:22</td>
<td>M. Eissel (Switzerland)</td>
</tr>
<tr>
<td>16:44</td>
<td>R. Clout (United Kingdom)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXXIV: Peer-to-peer learning session (P2P) in partnership with industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Reimbursement and premium CAR T - C. Uyl-de Groot (Netherlands)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXXV: Peer-to-peer learning session (P2P) in partnership with industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Reimbursement and premium CAR T - C. Uyl-de Groot (Netherlands)</td>
</tr>
</tbody>
</table>

**Closing Remarks**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XXXVI: Peer-to-peer learning session (P2P) in partnership with industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Reimbursement and premium CAR T - C. Uyl-de Groot (Netherlands)</td>
</tr>
</tbody>
</table>

**Closing Remarks**
Poster Index

Acute lymphoblastic leukemia
Biology & Translational Research

P01 A NOVEL BISPECIFIC CD19 AND CD22-DIRECTED CAR FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
S.R. Zanetti (Josep Carreras Leukemia Research Institute, Barcelona, Spain)

P02 SAFETY AND EFFICACY OF CD19 CAR T-CELLS AGAINST CNS LEUKEMIA
E. Jacoby (Sheba Medical Center, Tel Hashomer, Israel)

P03 EXPERIENCE IN CAR-T CELL THERAPY IN A PEDIATRIC INTENSIVE CARE UNIT
S. Bobillo (Hospital Sant Joan de Déu, Barcelona, Spain)

P04 IMMUNOLOGICAL CHANGES AFTER ANTI-CD19 CAR T-CELL THERAPY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
A. Deya-Martinez (Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain)

P05 UTILIZATION OF CAR-T CELL THERAPY IN PEDIATRIC PATIENTS, NURSING OVERVIEW AT SANT JOAN DE DÉU BARCELONA CHILDREN HOSPITAL
C. Llanos (Sant Joan de Déu Foundation, Sant Joan de Déu Research Institute, Esplugues de Llobregat, Spain)

P06 ACADEMIC, PHASE II/III TRIAL ON T CELLS EXPRESSING CD19 CHIMERIC ANTIGEN RECEPTORS AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA IN CHILDREN
F. del Bufalo (IRECS Ospedale pediatrico Bambino Gesù, Rome, Italy)

P07 APHERESIS LYMPHOCYTE COLLECTION FOR CAR T CELL PRODUCTION IN PEDIATRIC AND YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: THE SANT JOAN DE DÉU BARCELONA CHILDREN’S HOSPITAL EXPERIENCE.
S. Rivas (CAR-T Cell Unit, Hospital Sant Joan de Déu, Esplugues Llobregat, Barcelona, Spain)

P08 POST CAR T-CELL THERAPY PROGRESSIVE SUBRETINAL LEUKEMIC RELAPSE: A CASE REPORT.
B. Alhanyani (Children’s Hospital of Eastern Ontario, Ottawa, Canada)

P09 CAR-T CELLS FOR RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN THE EYE: A CASE REPORT
B.J. Vormoor-Burger (Prinses Maxima Center for Pediatric Oncology, Utrecht, The Netherlands)

Poster Index

Acute myeloid leukemia
Biology & Translational Research

P11 4-1BB-BASED CD123-REDIRECTED T-CELLS ABATE HUMAN NORMAL HEMATOPOIESIS IN VIVO
M. Libero Baroni (Josep Carreras Leukemia Research Institute, Barcelona, Spain)

P12 OPTIMIZED CART CELLS TARGETING CD33 FOR IMPROVED THERAPIES AGAINST R/R AML
J.R. Rodriguez-Madrazo (Hematology Oncology Programme, ClíMA Universidad de Navarra, IslSNA., Pamplona, Spain)

P13 NK92D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS
A.L. Leivas (Hospital Universitario 12 de Octubre, H12O-CNIO Haematological Malignancies Clinical, Madrid, Spain)

Chronic lymphocytic leukemia and related disorders
Biology & Translational Research

P14 IMPACT OF GENETICS ON THE PERFORMANCE OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
V. Marianova (Central European Institute of Technology (CEITEC), Brno, Czech Republic)

Myeloma and other monoclonal gammopathies
Biology & Translational Research

P15 PREFERENTIAL EXPANSION OF CD8+ T CELL CENTRAL MEMORY CELL SUBSET OF JNJ-4528 BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY: TRANSLATIONAL ANALYSIS FROM CARTITUDE-1, AN ONGOING PHASE 1/2 STUDY IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
E. Zudaire (Janssen R&D, Spring House, United States)

P16 T-CELL-EXPANSION AND TRANSDUCTION 3 MONTHS AFTER HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
T. Mika (Knappschaftskrankenhaus Bochum, Bochum, Germany)

P17 EARLY MEMORY CAR T CELLS WITH SUPERIOR EXPANSION CAPACITY USING TEMPORARY AKT INHIBITION
A.B. van der Waart (Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands)
Non-Hodgkin lymphoma

Clinical

P19 ASSESSING CLINICAL PARAMETERS PREDICTING CYTOKINE RELEASE SYNDROME (CRS) IN DLBCL PATIENTS UNDERGOING CAR-T THERAPY.
T. Patat (University Hospital, Bern, Switzerland)

P20 MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY
B.S. Imber (Memorial Sloan Kettering Cancer Center, New York City, United States)

P21 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENECILOLEUCEL (TISA-CELL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)
C.G. Oluwole (Vanderbilt-Ingram Cancer Center, Nashville, United States)

P22 OUTCOME AND CAUSES OF NON-ELIGIBILITY FOR CD19 CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
C. Carpio (Hospital Universitari Vall d’Hebron, Barcelona, Spain)

P23 INFLUENCE OF CD20- CD28- T-CELLS ON THE THERAPEUTIC OUTCOME IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY/DIFFUSE LARGE B-CELL LYMPHOMA AFTER CART-INFUSION
N.W. Worel (Medical University Vienna, Vienna, Austria)

P24 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS OF THE PHASE 2 ZUMA-2 STUDY
M.J. Konstan (Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands)

P25 A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA
S.S. Neelapu (The University of Texas MD Anderson Cancer Center, Houston, United States)

P26 AN OBSERVATIONAL PROSPECTIVE STUDY ON THE REAL LIFE ACCESSIBILITY TO CAR T CELLS: FROM CLINICAL FEASIBILITY TO MOLECULAR MONITORING OF DISEASE RESPONSE IN DIFFUSE LARGE B-CELL LYMPHOMAS
A. Guidetti (University of Milan & Fondazione IRCCS Istituto Nazionale del Tumore, Milan, Italy)

P27 THE IN-HOUSE MANUFACTURING PROCESS OF CD19 CAR-T FOR R/R NON-HODGKIN LYMPHOMA - EXPERIENCE OF A SINGLE CENTER
K. Ohmine (Jichi Medical University, Shimotsuke-shi, Japan)

P28 HYDROCORTISONE DURING CAR T INFUSION DOES NOT REDUCE CAR T CELL FUNCTION IN PATIENTS WITH ADRENAL INSUFFICIENCY
C.R. Schultz-Thuma (Hannover Medical School, Hannover, Germany)

P29 REAL-WORLD RESULTS OF AN ANTI-CD19 CAR T CELL AXICABTAGENE CILOLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA INCLUDED IN A FRENCH EARLY ACCESS PROGRAMME
C. Thieblemont (Hématologie, Assistance Publique Hôpitaux de Paris - Hôpital Saint-Louis, Paris, France)

P30 HEMATOXICITY AND INFECTION COMPLICATIONS OF CD19-CAR T CELL TREATED PATIENTS: REAL LIFE DATA FROM MUNICH (LMU)
K.R. Rejsek (LMU Munich, Munich, Germany)

P31 THE USE OF LIQUID BIOPSY FOR DISEASE MONITORING AFTER ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL IN DIFFUSE LARGE B-CELL LYMPHOMA
C. Matauquer Artigas (Institut Catala Oncologia - Hospital Darnall Reylans, Fundació IDibell, Hospitalitat De Llobregat, Spain)

P32 TREATMENT WITH CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AFTER A PRECEDING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (allo-HCT) IS FEASIBLE AND SAFE IN PATIENTS WITH B-CELL LYMPHOMA
M.L. Schulbert (University Hospital Heidelberg, Heidelberg, Germany)

P33 REAL-WORLD EVIDENCE OF THE USE OF TISAGENECILOLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS, THE SPANISH EXPERIENCE.
G. Iacoboni (Vall D’Hebron University Hospital, Barcelona, Spain)

P34 EARLY EXPERIENCE USING RADIOTHERAPY AS A SALVAGE TREATMENT FOR RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS FOLLOWING CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY
B.S. Imber (Memorial Sloan Kettering Cancer Center, New York City, United States)

P35 CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - THE MUNICH REAL LIFE EXPERIENCE
V. Büükdekin (University Hospital, LMU Munich, Munich, Germany)
**Poster Index**

**Gene therapy, cellular immunotherapy and vaccination Biology & Translational Research**

P36 NOVEL HUMANIZED ANTIBodies AND CAR-T AGAINST PRAME-POSITIVE TUMORS
A.V. Mityurin (GeneTechnology LLC, Moscow, Russia)

P37 CD19 REDIRECTED CAR NK CELLS ARE EQUALLY EFFECTIVE BUT LESS TOXIC THAN CAR T CELLS
C. Quintarelli (Bambino Gesù Children's Hospital, IRCCS, Rome, Italy)

P38 MEMORY STEM T CELLS (TSCM) TRANSDUCED WITH A CAR30 TARGETING A MEMBRANE-PROXIMAL CD30 EPITope CONFERS SUPERIOR T-CELL LYMPHOMA REACTIVITY IN VITRO AND A POTENT ANTITUMOR EFFECT IN VIVO
L. Escriva-Garcia (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

P39 SET UP OF A MANUFACTURING PLATFORM FOR DELIVERY OF MODIFIED T-CELLS FOR THERAPEUTIC APPLICATION: THE UCL TRANSLATION TEAM EXPERIENCE
A. Cadinisch-Garai (University College London, London, United Kingdom)

P40 COMPARISON OF MANUAL AND AUTOMATED CD19 CAR-T CELLS MANUFACTURING METHODOLOGIES
J. Dias (University College London, London, United Kingdom)

P41 HIGH CAR EXPRESSION CONFERS ENHANCED ANTITUMOR EFFECT AGAINST B-CELL AND Hodgkin's LYMPHOMA.
A. Caballer (Hospital de la Santa Creu i Sant Pau/Josep Carreras Leukemia Research Institute, Barcelona, Spain)

P42 PRECLINICAL ASSESSMENT OF EFFICACY AND SAFETY ANALYSIS OF THE CAR-T CELLS TARGETING CD19-EXPRESSING B CELLS FOR THE FIRST TURKISH ACADEMIC CLINICAL TRIAL WITH ALL AND NHL PATIENTS
Kamçı (Acıbadem Labodol) Laboratory, Istanbul, Turkey

P43 GAMMA-DELTA CAR T-CELLS SHOW CAR-DIRECTED AND INDIRECT ACTIVITY AGAINST LEUKEMIA
R.M. Rozenbaum (Tel Hashomer - Sheba medical center, Ramat Gan, Israel)

P44 GUT MICROBIOTA SIGNATURES AS PREDICTIVE BIOMARKERS FOR RESPONSE AND TOXICITIES IN BCP-ALL AND DLBCL PATIENTS AFTER TREATMENT WITH CD19 SPECIFIC CAR T CELLS
V. Blumenberg (University Hospital, LMU, Munich, Germany)

---

**Poster Index**

**Gene therapy, cellular immunotherapy and vaccination Clinical**

P45 IDENTIFICATION OF A TUMOR-SPECIFIC ALLO-HLA-RESTRICTED ??TCR
I. Johanns (University Medical Center Utrecht, Utrecht, The Netherlands)

P47 TEG001 INSERT INTEGRITY FROM VECTOR PRODUCER CELLS UNTIL MEDICINAL PRODUCT T. Stratemans (University Medical Center Utrecht, Utrecht, The Netherlands)

P48 CHARACTERISTICS OF ICU ADMISSIONS OF ADULT PATIENTS WITH B-CELL MALIGNANCIES TREATED WITH AR1-0001 CELLS (AN ACADEMIC CART-18)
P.C. Castro (Hospital Clinic de Barcelona, Barcelona, Spain)

P49 ADVERSE OUTCOME OF PATIENTS WITH LEG TYPE AND TRIPLE HIT LYMPHOMA AFTER CD19 CAR-T CELL THERAPY, A SINGLE CENTER EXPERIENCE
V.P. Victoria Panagioti (Hannover Medical School, Hannover, Germany)

P50 RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT
A.M. Berthelsen (Rigshospitalet, Copenhagen, Denmark)

P51 FLOWCHART FOR SYSTEMATIC DETECTION AND SYMPTOM MANAGEMENT OF CYTOKINE RELEASE SYNDROME POST CAR-T CELL TREATMENT
C. Borch Jacobsen (University Hospital of Copenhagen, Copenhagen, Denmark)

P52 GMP-COMPLIANT MANUFACTURING OF NKG2D CAR MEMORY T CELLS USING CLINIMACS PRODIGY
F. Fernández (CNIO, Madrid, Spain)

P53 LANGUAGE DYSFUNCTION ASSOCIATED EEG FINDINGS IN PATIENTS WITH CAR-T RELATED NEUROTOXICITY.
E. Sokolov (Massachusetts General Hospital, Boston, United States)

P54 CART19-BE:01: A EUROPEAN ACADEMIC TRIAL ON THE ADMINISTRATION OF AR1-0001 CELLS IN PATIENTS WITH CD19-LYMPHOPROLIFERATIVE DISORDERS
V. Ortiz-Maldonado (Hospital Clinic, Barcelona, Spain)

P55 DEVELOPMENT OF A KNOWLEDGE TEST ON IMMUNO-T, A MOTION COMIC EXPLAINING HOW 3 FORMS OF IMMUNOTHERAPY WORK.
T. Kerre (Ghent University Hospital, Ghent University, CanSoRG, Gent, Belgium)
**Poster Index**

**Clinical implementation of immune effector cell based therapies, including combinatorial approaches with other immune therapies**

**P56 THE HEIDELBERG 1 (HD-CAR-1 TRIAL): TREATMENT WITH CD-19-DIRECTED THIRD-GENERATION CAR T CELLS DISPLAYS AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**
M.J. Schubert (University Hospital Heidelberg, Heidelberg, Germany)

**P57 ALLOGENEIC HSCT AFTER CAR T CELLS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. BRIDGING ONLY AFTER CAR-T CELL LOSS?**
E. González Forster (Hospital Sant Joan de Déu, Barcelona, Spain)

**P58 CLINICAL IMPLEMENTATION AND EDUCATION: GETTING THE WIDER WORKFORCE READY FOR IMMUNE EFFECTOR CELLS**
L. McNab (The Christie NHS Foundation Trust, Manchester, United Kingdom)

**P59 NEUROLOGICAL MANAGEMENT AND WORK-UP OF 10 ADULT CAR T CELL PATIENTS WITH RELAPSED OR REFRACTORY B-CELL LYMPHOMA**
N. Möhn (Hannover Medical School, Hannover, Germany)

**P60 ANALYSIS OF CONTINUOUS REMISSION DUE TO CAR-T THERAPY IN A CASE OF DOUBLE EXPRESSION DIFFUSE LARGE B-CELL LYMPHOMA RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**
Y. Zang (Henan Provincial People's Hospital, People’s Hospital of Zhengzhou University, People’s Hospital, Zhengzhou, China)

**Solid tumor and autoimmune disorders**

**P61 "CAR T CELL TREATMENT FOR SOLID TUMOURS: YET NOT THERE"**
M.A. Sávio (HRS Oncologia D’or, UFBA, Salvador, Brazil)

**P62 ERBB2-CHIMERIC ANTIGEN RECEPTOR (CAR)-ENGINEERED NATURAL KILLER NK92-CELL LINE (NK92/8,26,7) FOR CLINICAL USE IN HIGH-RISK SOFT TISSUE SARCOMAS IN CHILDREN AND YOUNG ADULTS**
M. Marxer (University Hospital, Goethe University, Frankfurt/Main, Germany)

**Medico-economics, regulatory and patients acceptance aspects of CAR-T Cell therapies**

**P63 THE HUMANIZATION OF CARE FOR PATIENTS WHO PERFORM THERAPY CART IN AN ONCO-HEMATOLOGY PEDIATRIC UNIT**
M.A. Juncá Guillamés (Hospital Sant Joan de Déu, Barcelona, Spain)

**P64 SETTING UP A CAR T CELL UNIT CAN BE FACILITATED FROM PREVIOUS CLINICAL EXPERIENCE IN ALLOGENEIC BMT PATIENTS OF THE TEAM?**
D. Dubili (Istituto di Ematologia "Lorenzo e Artiosto Seragnoli", Poliemesico Universitario Sant’Orsola - Malpighi, Bologna, Italy)

**P65 LYMPHODEPLETION AND CAR-T INFUSION IN AMBULATORY CARE (AC) SETTING: A SAFE AND COST-EFFECTIVE APPROACH DELIVERING EXCELLENT PATIENT EXPERIENCE**
A.C. Colletta (University College London Hospitals NHS Trust, London, United Kingdom)

**P66 CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN CLINICAL TREATMENT OF CANCER PATIENTS: THE ROLE OF CAR-T SPECIALIST**
I. De Francesco (University of Pavia, Pavia, Italy)

**P67 STRATEGIES FOR THE IMPLEMENTATION AND DEVELOPMENT OF A CLINICAL PROGRAMME FOR CAR-T CELL THERAPY IN PATIENTS WITH REFRACTORY PRE-B ACUTE LYMPHOBLASTIC LEUKEMIA IN A DEVELOPING (LOW/MEDIUM-INCOME) COUNTRY**
A. Olaya-Vargas (National Institute of Pediatrics, Mexico City, Mexico)

**P68 FAILURE MODE, EFFECTS, AND CRITICALITY ANALYSIS (FMECA) OF CAR-T CELLS PHARMACEUTICAL CIRCUIT IN A FRENCH HOSPITAL**
M. Macrini (Saint-Louis Hospital, Paris, France)

**P69 EVALUATION OF LEUKOCYTOPHHEREISIS PERFORMED FOR THE PRODUCTION OF AN ACADMIC AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS**
J. Cid (Hospital Clínic, Barcelona, Spain)
ABIA HEREU, ANNA  
Hospital Vall d’Hebron, Barcelona, Spain  
Disclosures: No affiliations

ABRAMSON, JEREMY  
Massachusetts General Hospital, Boston, United States  
Disclosures: Abbvie (Consulting); Allogene (Consulting); Celgene (Consulting, research support); EMD Serono (Consulting); Genentech/Roche (Consulting); Karyopharm (Consulting); Kitex Pharma (Consulting); Morphosys (Consulting); Novartis (Consulting); Seattle Genetics (Research support)

AERTS, ERIK  
Haematology Nurses and Healthcare Professionals Group, Winterthur, Switzerland  
Disclosures: No affiliations

ALEXANDER, PHILIP  
King’s College Hospital, London, United Kingdom  
Disclosures: No affiliations

AMROLIA, PERSIS  
UCL Great Ormond Street Institute of Child Health, London, United Kingdom  
Disclosures: Autoles (Royalties for IP); Bluebird Bio (Research funding); Alkermes (Advisory board)

ASSEMACHER, MARIO  
Milenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany  
Disclosures: No affiliations

BADER, PETER  
University Hospital Frankfurt, Frankfurt, Germany  
Disclosures: Novartis (Consultancy, speaker’s bureau, honoraria); Medac (Research funding, patents and royalties, honoraria); Remez (Research funding, honoraria); Neovii (Research funding, honoraria); Jazz Pharmaceuticals (Honoraria); Amgen (Honoraria)

BARUCHEL, ANDRE  
Hôpital Robert Debre, Paris, France  
Disclosures: Novartis (Advisory boards, satellite symposium); Servier (Advisory boards, research grant); Celgene (Advisory board); Jazz (Advisory boards, satellite symposium); Amgen (Advisory board); Janssen (Satellite symposium); Astrazeneca (Satellite symposium)

BENJAMIN, REUBEN  
King’s College Hospital, London, United Kingdom  
Disclosures: Servier (Research funding); Pfizer (Research funding); Allogene (Research funding); Celgene (Advisory board); Gilade (Advisory board); Novartis (Advisory board); Takeda (Advisory board); EUJSA Pharma (Advisory board)

BERQUIER, MAXIME  
Hôpital Saint Louis, Paris, France  
Disclosures: Kite / Gilade (Advisory board, speaker); Novartis (Advisory board, speaker)

BOLAÑOS, NATACIA  
Lymphoma Coalition, Madrid, Spain  
Disclosures: No affiliations

BÖNING, HALWARD  
German Red Cross Blood Donation Service, Institute Frankfurt, Frankfurt, Germany  
Disclosures: Medac (Royalties, licensing fees); Therumo BCT (research support, honoraria, speakers fee, Advisory Board); Chugai (Research support, honoraria, speakers’ fee, Polyphor (Research support); Sandoz (Research support, honoraria, speakers’ fee, advisory board); Bayer (Research support); Unique (Research support); Erydel (Research support); Miltenyi (Research support, honoraria, speakers’ fee); Stage (Research support); Celgene (honoraria, speakers’ fee, advisory board); Fresenius (Honoraria, speakers’ fee); Kiadis (Honoraria, speakers’ fee); Genzyme (Advisory board); Novartis (Advisory board); Stage (Advisory board); Siemens Healthineers (Advisory board); Stock (Advisory board)

BONINI, CHIARA  
Ospedale San Raffaele, Milan, Italy  
Disclosures: Allogene (Advisory committee); GSK (Advisory committee); Intellia Therapeutics (Advisory committee, research funding); Kite/Gilead (Advisory committee); Molmed (Advisory committee); Novartis (Advisory committee); TcELL (Advisory committee)

BRIONES, JAVIER  
Hospital Santa Creu i Sant Pau, Barcelona, Spain  
Disclosures: Novartis (Advisory board); Celgene (Advisory board); Gilead (Research support, advisory board)

BÜSCH, DIRK  
Med, Microbiologie, Immunologie und Hygiene, Munich, Germany  
Disclosures: Affiliations unknown

CANO RUIZ, JOSEFA MARÍA  
Vall d’Hebron Hospital, Barcelona, Spain  
Disclosures: No affiliations

CHARANNON, CHRISTIAN  
Institut Paul-Clavelles & Aix-Marseille Université, Marseille, France  
Disclosures: Sanofi S.A. (Advisory board, speaker’s bureau, grant); Kite / Gilead (Advisory board, speaker’s bureau, hospitalities); Novartis (Speaker’s bureau); Celgene (Advisory board); Janssen (Advisory board); Becton (Advisory board); Therumo BCT (Speaker’s bureau); Fresenius Kabi (Research support); Miltenyi biotec (Research support)

CHOMIENNE, CHRISTINE  
IRSI, St Louis, Paris, France  
Disclosures: No affiliations

CICERI, FABIO  
San Raffaele Scientific Institute, Milan, Italy  
Disclosures: No affiliations
Faculty Index

CLOUT, RUTH
The Christie NHS Foundation Trust, Manchester, United Kingdom
Disclosures: Kite (Gilead); Speaker, honorarium

DUDEK, BETHANY
Kite Pharma, a Gilead Company, Amsterdam, The Netherlands
Disclosures: Kite Pharma, a Gilead Company (Employee)

EHNINGER, GERHARD
Technical University, Dresden, Germany
Disclosures: CoFlox (CEO); GEModB (CMO)

EINSELE, HERMANN
University Hospital Würzburg, Würzburg, Germany
Disclosures: Amgen (Research support, consultant, scientific advisory board, honorarium); Janssen (Research support, consultant, scientific advisory board, honorarium); Celgene (Research support, consultant, scientific advisory board, honorarium); BMS (Research support, consultant, scientific advisory board, honorarium); Novartis (Research support, consultant, scientific advisory board, honorarium); Takeda (Research support, consultant, scientific advisory board, honorarium)

ELLARD, ROSE LOUISE
Royal Marsden Hospital, London, United Kingdom
Disclosures: Mohrmed (Honoraria); Kite Gilead (Travel grant, honoraria)

GARCIA LOPEZ, TAMARA
The Christie NHS Foundation Trust, Manchester, United Kingdom
Disclosures: No affiliations

GRUBBEN, JOHN
Barst Cancer Institute, London, United Kingdom
Disclosures: Janssen (Grant funding, scientific advisory board, honoraria, PI of clinical trials); Acerta (Grant funding, honoraria); Celgene (Grant funding, scientific advisory board, honoraria); NIH (Grant funding); Welcome Trust (Grant funding); Cancer Research UK (Grant funding); MRC (Grant funding); AbbVie (Scientific advisory board, honoraria); Gilead (Scientific advisory board); Pharmacies (Scientific advisory board, honoraria, PI of clinical trials); Roche/Seventhech (Scientific advisory board, honoraria, PI of clinical trials); AstraZeneca (Honoraria); Morphosys (Honoraria); Kite Gilead (Honoraria, PI of clinical trials); BelGene (PI of clinical trials); Novartis (Honoraria, PI of clinical trials); Merck (PI of clinical trials); Epixyme (PI of clinical trials); Takeda (PI of clinical trials); TG Therapeutics (Honoraria, PI of clinical trials)

GUEDEAN CARRIO, SÓNIA
IDIBAPS, Barcelona, Spain
Disclosures: Gilead (Grant); Novartis (Patient holder)

HAAG, CORNELIA
University Hospital, Dresden, Germany
Disclosures: No affiliations

HEEMSKERK, MB JAM
LUMC, Leiden, The Netherlands
Disclosures: No affiliations

HERR, WOLFGANG
University Hospital Regensburg, Regensburg, Germany
Disclosures: No affiliations

HOSEN, NAOKI
Osaka University Graduate School of Medicine, Osaka, Japan
Disclosures: Osuka Pharmaceutical Co., Ltd. (Research funding)

HUIDECHEK, MICHAEL
Universitätsklinikum Würzburg, Würzburg, Germany
Disclosures: Universitätsklinikum Würzburg (Speaker’s bureau)

HUPPA, JOHANNES
Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria
Disclosures: No affiliations

HUTT, DAPHNA
Sheba Medical Center, Ramat Gan, Israel
Disclosures: No affiliations

IVICS, ZOLTAN
Paul Ehrlich Institute, Langen, Germany
Disclosures: No affiliations

JACOBY, ELAD
Sheba Medical Center, Tel Hashomer, Israel
Disclosures: Novartis (Honoraria); Lonza (Advisory board)

JACQUEMIN, VIRGINIE
Servier, Suresnes, France
Disclosures: Servier (Full-time employee)

JÄGER, ULRICH
Medical University of Vienna, Vienna, Austria
Disclosures: AbbVie (Research support); Amgen (Honoraria); ACP Orphan (Honoraria); Biogen (Research support, honoraria); BMS (Honoraria); Celgene (Research support, honoraria); Gilead (Research support, honoraria, advisory board); Janssen (Research support, honoraria, advisory board); Miltenyi (Honoraria, advisory board); MSD (Research support); Mundipharma (Honoraria, advisory board); Novartis (Research support, consultant, honoraria, advisory board); Roche (Research support, consultant, honoraria, advisory board); Sandoz (Honoraria); Takeda-Millennium (Research support, honoraria, advisory board)

JUAN OTERO, MANUEL
Hospital Clinic de Barcelona, Barcelona, Spain
Disclosures: No affiliations
JUNE, CARL  
University of Pennsylvania, Philadelphia, United States  
Disclosures: Affiliations unknown

KENYON, MICHELLE  
King’s College Hospital NHS Foundation Trust, London, United Kingdom  
Disclosures: Jazz Pharmaceuticals (Honoraria)

KERSTEN, MARIE JOSE  
Amsterdam UMC, Amsterdam, The Netherlands  
Disclosures: No affiliations

KÖHL, ULRIKE  
Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany  
Disclosures: No affiliations

KRÖGER, NICOLAUS  
University Medical Center Hamburg-Eppendorf, Hamburg, Germany  
Disclosures: Novartis (Honoraria, research funding); Riemser (Research funding); Celgene (Honoraria, research funding); Sanofi (Honoraria); Medac (Honoraria); Neovi (Honoraria, research funding)

KUBALL, JÜRGEN  
University Medical Center Utrecht, Utrecht, The Netherlands  
Disclosures: Novartis (Grant); Mithenyl (Grant); Gasbela (Shareholder, scientific advisor)

KÜNKELE, ANNETTE  
Charité - University Medicine Berlin, Berlin, Germany  
Disclosures: No affiliations

LATORRE, LUIS ALEJANDRO  
Spain  
Disclosures: Affiliations unknown

LEDERGERBER, DOROTHEA  
Novartis, Stein, Switzerland  
Disclosures: No affiliations

LEVINE, BRUCE  
University of Pennsylvania, Philadelphia, United States  
Disclosures: CRC Oncology (Consultancy fee); Novartis (Consultancy fee); Terumo (Consultancy fee); Lilly Asia Ventures (Consultancy fee); Aveceitas (Scientific advisory board); Brammer BioTHV (Viral Vector Services (Scientific advisory board); Immunex (Scientific advisory board); Ori Biotech (Scientific advisory board); Vycorix (Scientific advisory board); Trunity Therapeutics (Co-founder, equity holder)

LOCATELLI, FRANCO  
Sapienza University of Rome, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy  
Disclosures: Novartis (Advisory board, speaker’s bureau); Amgen (Advisory board, speaker’s bureau); Bluebird (Advisory board, speaker’s bureau); Mithenyl (Advisory board, speaker’s bureau)

MACKALL, CRYSTAL  
Stanford University, Stanford, United States  
Disclosures: Affiliations unknown

MACKENSEN, ANDREAS  
University Hospital of Erlangen, Erlangen, Germany  
Disclosures: No affiliations

MIELKE, STEPHAN  
Karolinska University Hospital, Stockholm, Sweden  
Disclosures: Gilead (Expert panel); Novartis (Speaker fees); Celgene (Speaker fee); Mithenyl (Speaker fee, data safety monitoring board); Kiadis Pharma (Speaker fee); Bellicum (Expert panel)

MOHTY, MOHAMAD  
INSERM, Paris, France  
Disclosures: Affiliations unknown

MURRAY, JOHN  
The Christie NHS FT, Manchester, United Kingdom  
Disclosures: Therosko (Speaker honoraria); Jazz (Speaker honoraria); Kite/Gilead (Speaker honoraria)

NAGLER, ARNON  
Chaim Sheba Medical Center, Ramat Gan, Israel  
Disclosures: No affiliations

NI CHONGHAILE, MAIREÁD  
HNHCP/ St James’s Hospital, Dublin, Ireland  
Disclosures: Jazz Pharmaceuticals (Speaker’s bureau, advisory board)

OSTUNI, EMANUELE  
Novartis, Switzerland  
Disclosures: Novartis (Head of Europe, Cell and Gene Therapy)

PAMIAS NOGUÉ, MARTA  
Institut Català d’Oncologia Hospitala, Barakona, Spain  
Disclosures: No affiliations

PASQUINI, MARCELO  
CIBMTR, Milwaukee, United States  
Disclosures: Novartis (Research support); Kite (Research support); Celgene (Research support, consultant); Amgen (Research support, consultant); Medigene (Consultant); Pfizer (Consultant)

PEDRAZZOLI, PAOLO  
IRCCS Fondazione San Matteo, Pavia, Italy  
Disclosures: No affiliations
Faculty Index

VERHOFSTRA, JURE
Foundation Hematology, Utrecht, The Netherlands
Disclosures: Amgen (Consultancy); Janssen (Speaker, patient advisory group); Takeda (Consultancy)

VICKERS, ELAINE
Science Communicated Ltd., Manchester, United Kingdom
Disclosures: No affiliations

WANG, JIAXIONG
Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
Disclosures: Celgene (Grant)

WELS, WINFRED
Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
Disclosures: No affiliations

YAKOUB-AGHA, IBRAHIM
Hopital Huriez, Lille, France
Disclosures: Gilead (Honorarium); Novartis (Honorarium); Celgene (Honorarium); Astellas (Honorarium)